AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...

ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

In a report released today, Emily Bodnar from H.C. Wainwright downgraded AnaptysBio (ANAB – Research Report) to a Hold, with a price target of ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

Anaptys Bio (NASDAQ:ANAB) stock plunged 33% Wednesday after the company said it was scrapping further development of its drug ...

AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a ...

The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, ...

The near-term catalysts include a Phase 2b trial for the drug candidates rosnilimab and ANB032, which are crucial for re-evaluating AnaptysBio’s stock value. Despite this promising pipeline and ...

The shift comes as the biotechnology company, currently valued at $759.5 million, braces for topline data from its Phase 2b trial of ANB032 in atopic dermatitis, expected later in December.